{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T05:32:21Z","timestamp":1767850341171,"version":"3.49.0"},"reference-count":44,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,12]]},"DOI":"10.1097\/fpc.0b013e328256b1b6","type":"journal-article","created":{"date-parts":[[2008,5,4]],"date-time":"2008-05-04T12:40:43Z","timestamp":1209904843000},"page":"1017-1029","source":"Crossref","is-referenced-by-count":83,"title":["Influence of mutations associated with Gilbert and Crigler\u2013Najjar type II syndromes on the glucuronidation kinetics of bilirubin and other UDP-glucuronosyltransferase 1A substrates"],"prefix":"10.1097","volume":"17","author":[{"given":"Wandee","family":"Udomuksorn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J.","family":"Elliot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin C.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter I.","family":"Mackenzie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krongtong","family":"Yoovathaworn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John O.","family":"Miners","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-2-20210212","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/0163-7258(91)90065-T","article-title":"Drug glucuronidation in humans","volume":"51","author":"Miners","year":"1991","journal-title":"Pharmacol Ther"},{"key":"R2-2-20210212","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1081\/DMR-100101944","article-title":"Structural and functional studies of UDP-glucuronosyltransferases","volume":"31","author":"Radominska-Pandaya","year":"1999","journal-title":"Drug Metab Rev"},{"key":"R3-2-20210212","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1146\/annurev.pharmtox.40.1.581","article-title":"Human UDP-glucuronosyltransferase: metabolism, expression, and disease","volume":"40","author":"Tukey","year":"2000","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"R4-2-20210212","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1097\/01.fpc.0000173483.13689.56","article-title":"Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily","volume":"15","author":"Mackenzie","year":"2005","journal-title":"Pharmacogenet Genom"},{"key":"R5-2-20210212","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev.pharmtox.44.101802.121546","article-title":"Predicting human drug glucuronidation parameters: application of in-vitro and in-silico modeling approaches","volume":"44","author":"Miners","year":"2004","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"R6-2-20210212","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S0300-483X(02)00449-3","article-title":"Genetic polymorphisms of UDP-glucuronosyltransferases and their functional significance","volume":"181\u2013182","author":"Miners","year":"2002","journal-title":"Toxicology"},{"key":"R7-2-20210212","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/1098-1004(200010)16:4<297::AID-HUMU2>3.0.CO;2-Z","article-title":"Genetic lesions of bilirubin uridine-diphospho-glucuronate glucuronosyltransferase (UGT1A1) causing Crigler\u2013Najjar and Gilbert syndromes: correlation of genotype to phenotype","volume":"16","author":"Kadakol","year":"2000","journal-title":"Hum Mutat"},{"key":"R8-2-20210212","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0168-8278(02)00359-8","article-title":"Inherited disorders of bilirubin metabolism","volume":"38","author":"Bosma","year":"2003","journal-title":"J Hepatol"},{"key":"R9-2-20210212","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1172\/JCI915","article-title":"Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoforms 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes","volume":"101","author":"Iyer","year":"1998","journal-title":"J Clin Invest"},{"key":"R10-2-20210212","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1042\/bj3030233","article-title":"Investigation of the substrate specificity of a cloned expressed human bilirubin UDP-glucuronosyltransferase: UDP-sugar specificity and involvement in steroid and xenobiotic glucuronidation","volume":"303","author":"Senafi","year":"1994","journal-title":"Biochem J"},{"key":"R11-2-20210212","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1097\/00008571-200211000-00008","article-title":"Pharmacophore and quantitative structure activity relationship modelling of UDP-glucuronosyltransferase 1A1 (UGT1A1) substrates","volume":"12","author":"Sorich","year":"2002","journal-title":"Pharmacogenetics"},{"key":"R12-2-20210212","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1093\/hmg\/4.7.1183","article-title":"Gilbert's syndrome is caused by a heterozygous missense mutation in the gene for bilirubin UDP-glucuronosyltransferase","volume":"4","author":"Koiwai","year":"1995","journal-title":"Hum Mol Genet"},{"key":"R13-2-20210212","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0925-4439(98)00013-1","article-title":"Contribution of two missense mutations (G71R and Y486D) of the bilirubin UDP glycosyltransferase (UGT1A1) gene of phenotypes of Gilbert's syndrome and Crigler\u2013Najjar syndrome type II","volume":"1406","author":"Yamamoto","year":"1998","journal-title":"Biochim Biophys Acta"},{"key":"R14-2-20210212","first-page":"21","article-title":"Neonatal hyperbilirubinemia and mutation of the bilirubin uridine diphosphate-glucuronosyltransferase gene: a common missense mutation among Japanese, Koreans and Chinese","volume":"46","author":"Akaba","year":"1998","journal-title":"Biochem Mol Biol Int"},{"key":"R15-2-20210212","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1111\/j.1440-1746.2004.03370.x","article-title":"Genetic polymorphisms of bilirubin uridine diphosphate-glucuronosyltransferase gene in Japanese patients with Crigler\u2013Najjar syndrome or Gilbert's syndrome as well as in healthy Japanese subjects","volume":"19","author":"Takeuchi","year":"2004","journal-title":"J Gastroenterol Hepatol"},{"key":"R16-2-20210212","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1046\/j.1442-200X.2002.01577.x","article-title":"Novel missense mutation of the UGT1A1 gene in Thai siblings with Gilbert's syndrome","volume":"44","author":"Sutomo","year":"2002","journal-title":"Pediatr Int"},{"key":"R17-2-20210212","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1111\/j.1440-1746.2004.03524.x","article-title":"What is Gilbert's syndrome? Lesson from genetic polymorphisms of UGT1A1 in Gilbert's syndrome from Asia","volume":"19","author":"Kamisako","year":"2004","journal-title":"J Gastroenterol Hepatol"},{"key":"R18-2-20210212","doi-asserted-by":"crossref","first-page":"8170","DOI":"10.1073\/pnas.95.14.8170","article-title":"Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism?","volume":"95","author":"Beutler","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R19-2-20210212","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/S0009-9236(99)70078-0","article-title":"Phenotype\u2013genotype correlation of in-vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism","volume":"65","author":"Iyer","year":"1999","journal-title":"Clin Pharmacol Ther"},{"key":"R20-2-20210212","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1124\/mol.62.3.608","article-title":"Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38)","volume":"62","author":"Gagne","year":"2002","journal-title":"Mol Pharmacol"},{"key":"R21-2-20210212","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1124\/dmd.31.1.108","article-title":"Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38), an active metabolite of irinotecan (CPT-11), by human UGT1A1 variants, G71R, P229Q, and Y486D","volume":"31","author":"Jinno","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"R22-2-20210212","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1124\/dmd.104.001800","article-title":"Racial variability in haplotype frequencies of UGT1A1 and glucuronidation activity of a novel single nucleotide polymorphism 686C>T (P229L) found in an African American","volume":"33","author":"Kaniwa","year":"2005","journal-title":"Drug Metab Dispos"},{"key":"R23-2-20210212","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1124\/mol.62.3.446","article-title":"Pharmacogenetics of human UDP-glucuronosyltranferases and irinotecan toxicity","volume":"62","author":"Tukey","year":"2002","journal-title":"Mol Pharmacol"},{"key":"R24-2-20210212","first-page":"6921","article-title":"polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis","volume":"60","author":"Ando","year":"2000","journal-title":"Cancer Res"},{"key":"R25-2-20210212","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00228-001-0417-2","article-title":"Effect of a conserved mutation in uridine diphosphate glucuronosyltransferase 1A1 and 1A6 on glucuronidation of a metabolite of flutamide","volume":"58","author":"Ito","year":"2002","journal-title":"Eur J Clin Pharmacol"},{"key":"R26-2-20210212","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1016\/j.bcp.2004.08.019","article-title":"The interactions between the N-terminal and C-terminal domains of the human UDP-glucuronosyltransferases are partly isoform-specific, and may involve both monomers","volume":"68","author":"Kurkela","year":"2004","journal-title":"Biochem Pharmacol"},{"key":"R27-2-20210212","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1124\/dmd.32.4.413","article-title":"Human UDP-glucuronosyltransferases: isoform selectivity and kinetics of 4-methylumbelliferone and 1-naphthol glucuronidation, effects of organic solvents, and inhibition by diclofenac and probenecid","volume":"32","author":"Uchaipichat","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"R28-2-20210212","doi-asserted-by":"crossref","first-page":"5222","DOI":"10.1210\/jc.2004-0331","article-title":"Specificity and regioselectivity of the conjugation of estradiol, estrone, and their catecholestrogen and methoxyestrogen metabolites by human uridine diphospho-glucuronosyltransferases expressed in endometrium","volume":"89","author":"Lepine","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"R29-2-20210212","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/j.bcp.2005.12.019","article-title":"In-vitro\u2014in-vivo correlation for drugs and other compounds eliminated by glucuronidation in humans: pitfalls and promises","volume":"71","author":"Miners","year":"2006","journal-title":"Biochem Pharmacol"},{"key":"R30-2-20210212","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/j.1365-2125.2005.02446.x","article-title":"S-naproxen and desmethylnaproxen glucuronidation by human liver microsomes and recombinant human UDP-glucuronosyltransferases (UGT): role of UGT2B7 in the elimination of naproxen","volume":"60","author":"Bowalgaha","year":"2005","journal-title":"Br J Clin Pharmacol"},{"key":"R31-2-20210212","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1124\/dmd.31.9.1086","article-title":"Isoform selectivity and kinetics of morphine 3-and 6-glucuronidation by human UDP-glucuronosyltransferases: evidence for atypical glucuronidation kinetics by UGT2B7","volume":"31","author":"Stone","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"R32-2-20210212","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1542\/peds.106.2.e17","article-title":"Noninvasive measurement of total serum bilirubin in a multiracial pre-discharge newborn population to assess the risk of severe hyperbilirubinemia","volume":"206","author":"Bhutani","year":"2000","journal-title":"Pediatrics"},{"key":"R33-2-20210212","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/0014-5793(71)80475-1","article-title":"Commercial bilirubin: a trinity of isomers","volume":"18","author":"McDonagh","year":"1971","journal-title":"FEBS Lett"},{"key":"R34-2-20210212","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S0378-4347(00)83835-9","article-title":"High-performance liquid chromatographic analysis of bile pigment as their native tetrapyrroles and as their dipyrrolic azosulfanilate derivatives","volume":"529","author":"Odell","year":"1990","journal-title":"J Chromatogr"},{"key":"R35-2-20210212","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1124\/dmd.105.005447","article-title":"In-vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in-vivo bilirubin glucuronidation","volume":"33","author":"Zhang","year":"2005","journal-title":"Drug Metab Disp"},{"key":"R36-2-20210212","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S0090-9556(24)15358-5","article-title":"In-vitro\u2014in-vivo scaling of CYP kinetic data not consistent with the classical Michaelis\u2013Menten model","volume":"28","author":"Houston","year":"2000","journal-title":"Drug Metab Dispos"},{"key":"R37-2-20210212","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1172\/JCI117604","article-title":"Discrimination between Crigler\u2013Najjar type I and II by expression of mutant bilirubin uridine diphosphate glucuronosyltransferase","volume":"94","author":"Seppen","year":"1994","journal-title":"J Clin Invest"},{"key":"R38-2-20210212","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1046\/j.1365-2125.2002.01669.x","article-title":"In-vitro\u2013in-vivo correlations for drugs eliminated by glucuronidation: investigations with the model substrate zidovudine","volume":"54","author":"Boase","year":"2002","journal-title":"Br J Clin Pharmacol"},{"key":"R39-2-20210212","doi-asserted-by":"crossref","first-page":"42108","DOI":"10.1074\/jbc.M106742200","article-title":"Homodimerization of human bilirubin uridine diphosphoglucuronate glucuronosyltransferase-1 (UGT1A1) and its functional implications","volume":"276","author":"Ghosh","year":"2001","journal-title":"J Biol Chem"},{"key":"R40-2-20210212","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/01.fpc.0000197465.14340.d4","article-title":"Relationship between hyperbilirubinaemia and UDP-glucuronosyltransferase 1A1 (UGT1A1) polymorphism in adult HIV-infected Thai patients treated with indinavir","volume":"16","author":"Boyd","year":"2005","journal-title":"Pharmacogenet Genom"},{"key":"R41-2-20210212","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1158\/1055-9965.EPI-03-0070","article-title":"Correlation between the UDP-glucuronosyltransferase (UGT1A1) TATAA box polymorphism and carcinogen detoxification phenotype: significantly decreased glucuronidating activity against benzo(a)pyrene-7,8-dihydrodiol(-) in liver microsomes from subjects with the UGT1A1*28 variant","volume":"13","author":"Fang","year":"2004","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"R42-2-20210212","first-page":"950","article-title":"Genetic polymorphism in uridine diphospho glucuronosyl transferase 1A1 and association with breast cancer among African Americans","volume":"60","author":"Guilemette","year":"2000","journal-title":"Cancer Res"},{"key":"R43-2-20210212","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1158\/0008-5472.CAN-03-3295","article-title":"The functional UGT1A1 promoter polymorphism decreases endometrial cancer risk","volume":"64","author":"Duguay","year":"2004","journal-title":"Cancer Res"},{"key":"R44-2-20210212","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1161\/CIRCULATIONAHA.106.633206","article-title":"Association between the UGT1A1*28 allele, bilirubin levels, and coronary heart disease in the Framingham Heart Study","volume":"114","author":"Lin","year":"2006","journal-title":"Circulation"}],"container-title":["Pharmacogenetics and Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FPC.0b013e328256b1b6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T01:48:14Z","timestamp":1738201694000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01213011-200712000-00002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,12]]},"references-count":44,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2007]]}},"URL":"https:\/\/doi.org\/10.1097\/fpc.0b013e328256b1b6","relation":{},"ISSN":["1744-6872"],"issn-type":[{"value":"1744-6872","type":"print"}],"subject":[],"published":{"date-parts":[[2007,12]]}}}